Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06450197 · ClinicalTrials.gov registry record · Phase 2

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

A Phase 2 study of Moderate to Severe Crohn's Disease, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT06450197: Active Phase 2 study of Moderate to Severe Crohn's Disease, sponsored by AstraZeneca.

NCT06450197 is a Phase 2 study of Moderate to Severe Crohn's Disease that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06450197, a Phase 2 study of Moderate to Severe Crohn's Disease, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.

Primary Outcome

Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. It is based on: number of loose stools, abdominal pain, general well-being, extraintestinal complications, antidiarrheal agents used in the previous 7 days, abdominal mass felt on palpation, hematocrit and body weight

Conditions Studied

Moderate to Severe Crohn's Disease

Interventions

  • OTHER Placebo
  • DRUG AZD7798

Study Locations (20)

Texas

  • Research Site - Dallas
  • Research Site - Garland
  • Research Site - Mansfield
  • Research Site - San Antonio

California

  • Research Site - Escondido
  • Research Site - La Jolla
  • Research Site - Victorville

North Carolina

  • Research Site - Asheville
  • Research Site - Charlotte
  • Research Site - Winston-Salem

Florida

  • Research Site - Orlando
  • Research Site - Tampa

Missouri

  • Research Site - Liberty
  • Research Site - St Louis

Arizona

  • Research Site - Phoenix

Connecticut

  • Research Site - Hamden

Idaho

  • Research Site - Idaho Falls

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-08-28
Est. Completion 2027-05-14
Phase Phase 2
AstraZeneca

1,285 total trials

What the registry record for NCT06450197 still lists

NCT06450197 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).

The record links to 1 condition, with Moderate to Severe Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06450197 names 20 study sites across 11 states, led by Texas, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06450197 about?

NCT06450197 is a clinical study titled "Phase IIa Study Evaluating AZD7798 in Crohn's Disease". This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.

What is the current status of trial NCT06450197?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-08-28. Estimated completion is 2027-05-14.

What conditions does trial NCT06450197 study?

This clinical trial studies the following conditions: Moderate to Severe Crohn's Disease.

What interventions are being tested in trial NCT06450197?

The interventions under investigation include: Placebo (OTHER), AZD7798 (DRUG).

Who is sponsoring clinical trial NCT06450197?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06450197 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT06450197's enrollment target sits among peer trials

120 569th of 2000 higher than 1,383 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06450197, the US trial registry maintained by the National Library of Medicine. NCT06450197 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.